MELISSA NOYES: Open Payments
NPI 1801244074 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,140 in 36 payments from 19 companies in 2025. Trend: 2023 $165 · 2024 $1,407 · 2025 $1,140
Food & beverage: $1,040Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $198 |
| Incyte Corporation | 3 | $163 |
| GlaxoSmithKline, LLC. | 2 | $139 |
| SEAGEN INC. | 1 | $100 |
| Janssen Biotech, Inc. | 3 | $75 |
| Genmab U.S., Inc. | 2 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Merck Sharp & Dohme LLC | 2 | $41 |
| GENZYME CORPORATION | 1 | $37 |
Products named: Niktimvo, ZEJULA, Tivdak, IMFINZI, LYNPARZA, Onivyde, KEYTRUDA, JAKAFI.
Industry payments across AZ — which companies pay providers there.
